Therapeutic Effects of Berberine in Patients With Type 2 Diabetes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether berberine is effective in the treatment of type 2 diabetes.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes |
Drug: Berberine Drug: Metformin |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Berberine on Improvement of Glucose and Lipid Metabolism in Patients With Type 2 Diabetes |
- HbA1c at 13 weeks
- Blood glucose at 13 weeks
- Blood lipids at 13 weeks
| Estimated Enrollment: | 70 |
| Study Start Date: | January 2004 |
| Estimated Study Completion Date: | December 2004 |
Type 2 diabetes is health threats worldwide. However, treatment of this disease is limited by availability of effective medicines. All of the existing oral hypoglycemic agents have secondary failure after long term administration. Thus, new oral medicines are needed for long term control of blood glucose in patients with type 2 diabetes. In diabetes care, dietary approaches have drawn more and more attention in the prevention and treatment of hyperglycemia. Generally regarded as safe (GRAS) plants have been widely used for their benefits in antioxidation, anti-inflammation, anticancer, anti-obesity and anti-diabetes. Numerous botanical products such as pigments that include anthocyanins and flavonoids have been consumed or studied for anti-obesity and anti-diabetes. However, most of these botanical products are mixtures of multiple compounds. It is difficult to control their quality in the study or production. Up to now, as a single purified compound, berberine is demonstrated to have hypoglycemic effect in vitro and in vivo. Berberine is the main active component of Coptis chinensis French, which was used for thousands of years in China in the treatment of human diseases including diabetes.
Comparison(s): Effects of berberine compared with metformin in newly diagnosed type 2 diabetic patients.
Eligibility| Ages Eligible for Study: | 25 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of type 2 diabetes
- HbA1c > 7.0% or FBG > 7.0 mmol/L
- Stable or worsening glycemic control for at least 3 months
Exclusion Criteria:
- Liver damage
- Kidney damage
Contacts and Locations| China | |
| Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine | |
| Shanghai, China, 200092 | |
| Principal Investigator: | Jun Yin, MD, PhD | Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00425009 History of Changes |
| Other Study ID Numbers: | XH-2002-Clin4 |
| Study First Received: | January 18, 2007 |
| Last Updated: | January 18, 2007 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Shanghai Jiao Tong University School of Medicine:
|
Berberine Type 2 diabetes Treatment |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013